earnings
confidence high
sentiment positive
materiality 0.85
Upstream Bio Q3 loss $33.7M; VIBRANT Ph2 CRSwNP meets primary endpoint
Upstream Bio, Inc.
2025-Q3 EPS
reported -$1.88
vs consensus -$0.79
▼ miss
(-138.0%)
- VIBRANT Ph2 met primary endpoint: placebo-adjusted NPS reduction of -1.8 (p<0.0001) at 24 weeks.
- Key secondary endpoints met: 76% reduction in need for surgery/systemic corticosteroids (p=0.03).
- Cash $372.4M as of Sept 30, 2025; expected to fund operations through 2027.
- Net loss $33.7M vs $16.0M YoY; R&D expense rose to $33.0M from $15.4M on verekitug costs.
- VALIANT Ph2 severe asthma top-line due Q1 2026; VENTURE Ph2 COPD enrollment ongoing.